Key Takeaways
- Substance use disorders cost the United States more than $700 billion a year, according to NIDA. The White House Council of Economic Advisers estimated in 2025 that the opioid epidemic alone imposed costs of $2.7 trillion in 2023, equivalent to roughly 9.7 percent of GDP.
- NIDA research finds that every dollar invested in addiction treatment yields between four and seven dollars in reduced crime, criminal justice costs, and theft. When healthcare savings are included, total offsets can exceed costs by a ratio of twelve to one. A separate ONDCP-cited analysis put the average cost of treatment at $1,583 per patient against an associated cost offset of $11,487.
- Payer siloing is the structural reason the economic case hasn’t translated into reimbursement. Behavioral health benefits have historically been managed in separate administrative structures with their own budgets and performance metrics, severing the data link between addiction treatment spending and its downstream medical effects.
- The addiction treatment sector lacks standardized outcomes measurement. Without agreed-upon metrics applied consistently across providers, the twelve-to-one figure remains peer-reviewed but not payer-validated, functioning as an advocacy argument rather than a pricing mechanism.
- Value-based contracting is the next logical step but requires data infrastructure the sector has not yet built. Recovery Centers of America CEO Brett Cohen pointed to RCA’s September 2025 in-network expansion with Optum as an early step toward the payer relationships that would make outcome-linked payment structures possible.
- Stigma functions as an economic force, not just a cultural one. It shapes reimbursement policy, zoning decisions, employer benefit design, and legislative priorities. The gap between what cost-offset data suggests addiction treatment is worth and what the market currently pays is a rough measure of what stigma costs the system.
- Private equity investment in addiction treatment has lagged other healthcare verticals. Cohen attributed this partly to stigma and partly to the industry’s origins in out-of-network, destination-style care models that didn’t fit institutional investment frameworks. He described the sector as still in “early innings.”
The Economic Case for Addiction Treatment
Substance use disorders cost the United States more than $700 billion a year, according to the National Institute on Drug Abuse. A 2023 CDC study published in the American Journal of Preventive Medicine put just the productivity losses, including missed work, reduced job performance, and inability to hold employment, at nearly $93 billion in a single year. The White House Council of Economic Advisers estimated in 2025 that the opioid epidemic alone imposed costs of $2.7 trillion in 2023, equivalent to roughly 9.7 percent of GDP, when factoring in premature death and diminished quality of life. By almost any measure, addiction ranks among the most expensive public health crises in the country.
The counterpoint to those figures has circulated in policy and provider circles for years: treatment works, and it pays for itself. NIDA’s own analysis found that every dollar invested in addiction treatment yields between four and seven dollars in reduced drug-related crime, criminal justice costs, and theft. When savings related to healthcare are included, fewer emergency department visits, fewer hospitalizations, and reduced chronic disease progression, total savings can exceed costs by a ratio of twelve to one. A separate analysis cited by the Office of National Drug Control Policy put the average cost of treatment at $1,583 per patient and the associated cost offset at $11,487, a greater than seven-to-one return even before accounting for the broadest downstream effects.
Brett Cohen, president and CEO of Recovery Centers of America, has internalized those numbers as both a talking point and a conviction. In an interview with Acuity Media Network, Cohen cited the twelve-to-one figure three times in thirty minutes, each time anchoring it to a different facet of the industry’s challenge. “For every dollar invested in addiction care, it saves twelve dollars in non-addiction medical care,” he said. “Think about emergency room visits, hospitalizations, long-term damage to your liver and other organs.”
The statistic, rooted in NIDA research and reinforced by the 2016 Surgeon General’s report on alcohol, drugs, and health, captures the upper bound of a well-documented range. It accounts not only for direct treatment savings but for the cascading costs that untreated substance use disorders impose across the healthcare system: patients cycling through emergency departments, accumulating chronic conditions, generating expenditures that dwarf the price of structured intervention. The logic has never been seriously disputed. The question has always been why it hasn’t changed the market.
Behavioral Health Siloing Is Why Addiction Treatment ROI Doesn’t Move Payer Decisions
If the economic case for addiction treatment delivers anything close to a twelve-to-one return, it should, in theory, attract the kind of payer enthusiasm reserved for high-value interventions. Instead, reimbursement rates for residential SUD care remain well below what the cost-offset data would suggest, and the sector has historically struggled to command the investment and institutional credibility of other healthcare verticals. Cohen offered a structural diagnosis: payers silo their behavioral health spending from the rest of their medical book, making it nearly impossible to see the full picture.
“Payers who silo their behavioral health from the rest of healthcare don’t cross-fertilize those outcomes and those measurement metrics,” he said. The result: the entity paying for residential addiction treatment often cannot easily determine whether that investment reduced the same patient’s ER visits, hospitalizations, or chronic disease progression. The twelve-dollar savings may be real, but if no one tracks it across the ledger, it remains an argument rather than a line item.
The siloing problem has deep roots in how behavioral health benefits were historically managed. For decades, many commercial and Medicaid plans carved out behavioral health into separate administrative structures, managed by specialty vendors with their own budgets, networks, and performance metrics. The model was designed to contain costs, and it did: a seminal Health Affairs study found that behavioral health carve-outs reduced plan costs by 30 to 40 percent. But the same structure that controlled spending also severed the data link between behavioral health interventions and their downstream medical effects.
The industry has begun to recognize the problem. At a 2022 Behavioral Health Business conference, Dr. Katherine Knutson, then a senior vice president at UnitedHealth Group and CEO of Optum Behavioral Care, said the company was working to eliminate carve-outs in favor of a total-cost-of-care approach. “That is the work that we’re doing,” she said. “We’re pushing very hard with a lot of promising models to really move forward.” And in a Behavioral Health Business survey of industry leaders published ahead of 2025, multiple executives pointed to integrated physical and behavioral health models as a defining trend, with some noting that payers were beginning to recognize that mental health spending could affect total medical costs. But progress has been uneven: a separate analysis found that integrated managed care organizations had not yet outperformed carve-outs on behavioral health access metrics, suggesting the structural transition remains early.
Without Standardized Outcomes Data, the Economic Case Stays an Argument, Not a Line Item
The siloing problem compounds a second, more fundamental challenge: the addiction treatment industry has not yet reached consensus on how to measure its own results. Cohen acknowledged that “there’s limited consensus on outcomes” across the sector, and that the metrics providers do track are applied inconsistently from one organization to the next. Without standardized measurement, the evidence base for the economic argument remains softer than its proponents would like.
This matters because the twelve-to-one figure, while grounded in peer-reviewed research, draws from studies that vary in methodology, population, and scope. NIDA’s widely cited range of four to seven dollars in crime and justice savings comes from aggregate analyses across treatment modalities and populations. The twelve-to-one upper bound, which includes healthcare offsets, reflects the broadest possible accounting.
Whether those savings apply uniformly to residential treatment, outpatient care, medication-assisted treatment, or some combination depends on variables that the industry has not yet systematically tracked.
The lack of standardized outcomes measurement constrains not only the economic argument but the next step Cohen envisions: value-based contracting with commercial payers. “You can start thinking differently about what that looks like and really differentiate based on quality,” he said, referencing RCA’s recent in-network expansion with Optum. “Think about value-based contracting or different payer structures that you can’t achieve in an out-of-network model.” But value-based contracting requires agreed-upon metrics, reliable data collection, and a willingness on both sides to tie payment to performance, none of which the residential SUD sector has fully developed. The growing role of AI-driven analytics in behavioral health may eventually accelerate that infrastructure, but the clinical and administrative groundwork still needs to be laid.
Private Equity Investment in Addiction Treatment: Why the Sector Has Lagged Other Healthcare Verticals
The twelve-dollar argument also carries implications for the capital flowing into addiction treatment. Cohen noted that the SUD sector has historically struggled to attract the same level of private equity investment seen in other behavioral health verticals, in part because of stigma and in part because the industry grew up around out-of-network, destination-style treatment models that did not fit neatly into institutional investment frameworks.
“Initially when the first providers got into addiction, it was set up as an out-of-network, destination-type industry,” Cohen said. “So it wasn’t the type of company that a PE firm serious about healthcare really put a lot of money into early on.” He predicted that as the industry matures, professionalizes its operations, and demonstrates the economic case more rigorously, investment will follow. “We’re in early innings right now,” he said.
Whether “early innings” is a fair characterization or a generous one depends on how you measure the clock. The addiction treatment industry has been making the cost-offset argument for decades. NIDA published its four-to-seven-dollar savings estimate in the early 2000s; the Surgeon General’s report codified the broader cost-benefit case in 2016. What the sector has not yet produced is large-scale, payer-validated evidence that would convert the twelve-dollar statistic from an advocacy talking point into a pricing mechanism.
The investment picture has shifted, at least at the upper end of the market. RCA’s backer, Deerfield Management, has been one of the largest private investors in addiction treatment since the company’s founding in 2014. Cohen described the firm as one that “sees a need for ongoing investment in high-quality behavioral health care” and drew a distinction between patient capital and the kind of short-horizon PE that has drawn criticism across behavioral health platform building. “The PE firms that are patient and able to invest for the long term are really making a difference,” he said. “If a PE firm is looking to turn it around quickly and flip a company, I don’t think that’s helpful.”
How Stigma Functions as an Economic Barrier to Addiction Treatment Funding
Cohen repeatedly returned to stigma as both a cultural barrier and a financial one. “Historically there’s been a lot of stigma,” he said. “Not just from the investor community or the payer community, but from neighbors and family and friends. It’s not something that’s often talked about because it’s historically been seen as a weakness, which it’s not. It’s a true illness.”
The framing matters beyond rhetoric. Stigma shapes reimbursement policy, zoning decisions, legislative priorities, and employer willingness to fund robust behavioral health benefits. When RCA was building its early campuses, the company encountered legal challenges from communities resisting the placement of treatment facilities in their neighborhoods, a pattern well documented across the industry. To the extent that the twelve-dollar argument reflects reality, the gap between what the data suggests and what the market delivers functions as a rough measure of what stigma costs the system.
Closing that gap may require more than better data, though better data would help. It may require the kind of structural shift that Cohen and other industry leaders have described: moving addiction treatment from a siloed, out-of-network, episodic model into the mainstream of American healthcare, where it can be measured, benchmarked, and paid for on the same terms as the chronic conditions it most closely resembles. The twelve-dollar figure has been making the case for years. What remains to be seen is whether the institutions that finance healthcare are finally ready to test it.
Frequently Asked Questions
What does the $12-to-$1 addiction treatment return on investment figure actually measure?
The twelve-to-one figure represents the upper bound of a well-documented range of economic returns associated with addiction treatment investment. It draws primarily from NIDA research and the 2016 Surgeon General’s report on alcohol, drugs, and health. NIDA’s own analysis found that every dollar invested in addiction treatment yields between four and seven dollars in reduced drug-related crime, criminal justice costs, and theft. When healthcare savings are added, including reduced emergency department visits, fewer hospitalizations, and lower chronic disease progression costs, total offsets can exceed costs by a ratio of twelve to one. A separate analysis cited by the Office of National Drug Control Policy put the average cost of treatment at $1,583 per patient against an associated cost offset of $11,487. The figure reflects the broadest possible accounting and should be understood as an upper-bound estimate rather than a uniform return applicable to every treatment modality.
Why don’t payers act on the addiction treatment cost-offset data?
The primary structural reason is behavioral health siloing. For decades, many commercial and Medicaid plans managed behavioral health in separate administrative structures, with their own budgets, networks, and performance metrics. A seminal Health Affairs study found that these carve-out arrangements reduced plan costs by 30 to 40 percent, giving payers a financial incentive to maintain them. But the same structure severed the data link between behavioral health interventions and downstream medical savings. The entity paying for residential addiction treatment typically cannot easily determine whether that investment reduced the same patient’s ER visits or hospitalizations. If no one tracks the twelve-dollar savings across the full ledger, it remains an advocacy argument rather than a line item that affects reimbursement decisions.
What is behavioral health siloing and why does it matter for addiction treatment funding?
Behavioral health siloing refers to the administrative separation of mental health and substance use disorder benefits from the rest of a health plan’s medical book. Under a carved-out model, a specialty vendor manages behavioral health with a separate budget, separate provider network, and separate performance metrics. While this approach was designed to contain costs, it means the economic benefits of addiction treatment, including reduced emergency department utilization, fewer hospitalizations, and lower chronic disease costs, are captured in the medical budget rather than the behavioral health budget. The payer paying for treatment often cannot see the savings it generates, which makes it structurally difficult to justify higher reimbursement rates. Recovery Centers of America CEO Brett Cohen described the result plainly: “Payers who silo their behavioral health from the rest of healthcare don’t cross-fertilize those outcomes and those measurement metrics.”
How does the lack of standardized outcomes measurement in addiction treatment affect payer decisions?
Without agreed-upon outcomes metrics applied consistently across providers, the economic argument for addiction treatment cannot be validated at the payer level. The twelve-to-one figure is grounded in peer-reviewed research, but the underlying studies vary in methodology, population, and scope. Whether those savings apply uniformly to residential treatment, outpatient care, medication-assisted treatment, or some combination depends on variables the industry has not yet systematically tracked. This gap constrains value-based contracting, which requires agreed-upon metrics and reliable data collection before either side will tie payment to performance. The development of AI-driven analytics tools in behavioral health may eventually support better longitudinal data collection across the care continuum, but clinical and administrative standardization is the prerequisite the industry still needs to establish.
Why has private equity investment in addiction treatment lagged other behavioral health sectors?
Two structural factors account for most of the gap. First, the addiction treatment industry developed around out-of-network, destination-style care models that generated revenue through high-margin cash-pay or out-of-network reimbursement rather than the scalable, in-network frameworks that institutional investors prefer. Second, stigma suppressed demand for structured, clinically rigorous treatment in ways that made it difficult to project stable revenue. As Cohen put it, it “wasn’t the type of company that a PE firm serious about healthcare really put a lot of money into early on.” The broader behavioral health consolidation wave driven by private equity has been concentrated in sectors with more predictable reimbursement dynamics. Addiction treatment is beginning to attract sustained institutional capital as providers professionalize, move in-network, and build the clinical infrastructure needed to demonstrate outcomes, but Cohen described the sector as still in “early innings.”
What would it take to convert the addiction treatment ROI argument into a pricing mechanism?
Three things are required. First, the dismantling of behavioral health carve-outs in favor of total-cost-of-care models that allow payers to track the downstream medical savings of addiction treatment within the same administrative structure that pays for it. Second, standardized outcomes measurement applied consistently across providers, giving payers and providers a shared empirical basis for value-based arrangements. Third, large-scale, payer-validated evidence that converts the aggregate academic findings into the kind of facility-level and population-level data that shapes coverage and reimbursement decisions. RCA’s in-network expansion with Optum in September 2025 is a step toward the payer relationships that could generate that evidence. Whether scaled behavioral health platforms can produce it at meaningful volume, and whether payers will act on it when they do, is the central question the sector has been circling for two decades.
